Mavixen

Protease inhibitors attack hepatitis C virus at a completely different step than sofosbuvir and velpatasvir do — rather than blocking the virus from copying its genetic material or assembling its replication machinery, glecaprevir disrupts something that happens even earlier in the viral life cycle: the processing of one giant viral protein into the individual functional pieces the virus actually needs.

The basic biology — HCV makes one giant protein first, then cuts it apart

When HCV infects a liver cell and begins using the cell’s machinery to make new viral proteins, it doesn’t produce each of its individual proteins separately the way you might expect. Instead, the virus’s RNA genome is translated into one single, enormous chain of protein called a polyprotein — essentially all of the virus’s proteins strung together end to end, like a long sentence with no spaces between the words.

This polyprotein is completely non-functional in its initial form. None of the individual viral proteins can do their job while they’re still fused together in this giant chain — they need to be precisely cut apart at specific points to release each individual, functional protein, including the structural proteins that form new virus particles and the non-structural proteins (like NS5A and NS5B, which we discussed with velpatasvir and sofosbuvir) that the virus needs to replicate.

The enzyme responsible for this cutting — NS3/4A protease

The job of cutting this polyprotein into its individual functional pieces falls to a specific viral enzyme: the NS3/4A protease. A protease is simply an enzyme that cuts proteins at specific locations, and HCV’s NS3/4A protease is responsible for several of the critical cleavage events needed to liberate the individual non-structural proteins from the polyprotein chain — proteins the virus absolutely requires to replicate, including NS5A and NS5B themselves.

In other words: before NS5A can do its organizational job, and before NS5B can start copying viral RNA, both of these proteins first need to be cut free from the larger polyprotein chain by NS3/4A protease. This makes NS3/4A protease a foundational, upstream step that everything else in viral replication depends on.

How glecaprevir disrupts this process

Glecaprevir is a protease inhibitor — it works by binding directly to the active site of the NS3/4A protease, the specific pocket on the enzyme where it would normally grab and cut the polyprotein chain. By occupying this site, glecaprevir physically blocks the protease from performing its cutting function.

With NS3/4A protease disabled, the polyprotein never gets properly processed into its individual functional pieces. The viral proteins remain stuck together in their original, non-functional chain — NS5A can’t do its assembly job, NS5B can’t copy RNA, and the entire downstream replication process that depends on these properly liberated proteins simply never gets started. It’s a bit like jamming a pair of scissors that’s supposed to cut a long strip of paper into individual labeled pieces — without that cutting step, none of the individual pieces can be used for their intended purpose, no matter how good those pieces might be on their own.

Why combining a protease inhibitor with an NS5A inhibitor makes sense

This explains the logic behind pairing glecaprevir with pibrentasvir in the same pill. Glecaprevir blocks an early, upstream step (cutting the polyprotein), while pibrentasvir (the NS5A inhibitor) blocks a separate, downstream step (organizing the replication complex) — even in the rare case where some polyprotein processing manages to occur despite glecaprevir’s presence. This is the same two-different-mechanisms principle we discussed with sofosbuvir and velpatasvir: attacking two genuinely independent steps in the viral life cycle makes it dramatically harder for the virus to develop resistance to both simultaneously, since escaping one drug’s pressure doesn’t help the virus escape the other.

Why this is a genuinely different drug class than sofosbuvir

This is worth being explicit about, since these drugs are often grouped together loosely as “direct-acting antivirals.” Sofosbuvir works by directly sabotaging the RNA-copying process itself, getting incorporated into newly made viral RNA and acting as a chain terminator. Glecaprevir works upstream of that entirely, by preventing the viral proteins needed for replication from ever becoming functional in the first place. These are mechanistically distinct strategies that happen to converge on the same overall goal — stopping the virus from successfully replicating inside liver cells.

Why resistance mutations to protease inhibitors can develop, and why this matters clinically

Because the NS3/4A protease’s active site is the direct target, mutations in the gene encoding this protease can sometimes alter the shape of that active site enough to reduce how well glecaprevir binds, while still allowing the enzyme to do its normal cutting job — this is the basis for resistance-associated substitutions that researchers track in clinical studies. This is part of the reason pibrentasvir is included alongside glecaprevir rather than using a protease inhibitor alone, and it also explains why genotype 1 patients who’ve previously failed a protease-inhibitor-containing regimen specifically aren’t eligible for retreatment with glecaprevir/pibrentasvir’s combination — their virus may already carry resistance patterns that would blunt glecaprevir’s effectiveness the second time around, which connects directly to the eligibility criteria we discussed for the Mavixen product page.

The bigger picture

Glecaprevir represents a third distinct strategy for attacking HCV, alongside the polymerase-inhibition strategy of sofosbuvir and the replication-complex-disruption strategy of velpatasvir and pibrentasvir. By targeting the very first processing step the virus needs to convert its genetic blueprint into functional, individual proteins, protease inhibitors like glecaprevir prevent the entire downstream replication cascade from ever getting underway — a strategy that, when combined with a second drug targeting a separate step, has proven remarkably effective at achieving the high cure rates we’ve discussed throughout this comparison.